Effect of accelerated infliximab induction on short-and long-term outcomes of acute severe ulcerative colitis: a retrospective multicenter study and meta-analysis

N Nalagatla, K Falloon, G Tran, NZ Borren… - Clinical …, 2019 - Elsevier
Background & Aims In patients with acute severe ulcerative colitis (ASUC), standard
infliximab induction therapy has modest efficacy. There are limited data on the short-term or …

Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study

T Adar, D Faleck, S Sasidharan… - Alimentary …, 2019 - Wiley Online Library
Background The older patient group with inflammatory bowel diseases (IBD) is particularly
vulnerable to consequences of disease and therapy‐related side effects but little is known …

Faecal microbiota transplantation as a treatment for inflammatory bowel disease: a national survey of adult and paediatric gastroenterologists in the UK

JR Mcilroy, N Nalagatla, R Hansen, A Hart… - Frontline …, 2018 - fg.bmj.com
Background Interest in the use of faecal microbiota transplantation (FMT) in inflammatory
bowel disease (IBD) has increased following outcomes in patients with Clostridioides …

A National Audit of Uveal Melanoma Referrals in Scotland

N Nalagatla, R Davies, J Connolly, P Cauchi… - Eye, 2022 - nature.com
The Royal College of Ophthalmologists (RCOphth) has published guidelines for referring
patients with suspected adult ocular tumours in the UK [1]. In recent years, there has been a …

PWE-039 FMT as a treatment for IBD: a national survey of gastroenterologists in the UK

J Mcilroy, N Nalagatla, R Hansen, A Hart, G Hold - 2018 - gut.bmj.com
Introduction Interest in the use of faecal microbiota transplantation (FMT) as a therapeutic
treatment in inflammatory bowel disease (IBD) has increased following promising outcomes …

[CITATION][C] Su1857–Comparative Safety and Effectiveness of Tumor Necrosis Factor Alpha Antagonists and Vedolizumab in Older IBD Patients: A Multicenter Study

T Adar, D Faleck, S Sasidharan, KC Cushing… - Gastroenterology, 2019 - Elsevier

[CITATION][C] COMPARATIVE SAFETY AND EFFECTIVENESS OF TUMOR NECROSIS FACTOR ALPHA ANTAGONISTS AND VEDOLIZUMAB IN OLDER IBD …

T Adar, D Faleck, S Sasidharan… - …, 2019 - … CO-ELSEVIER INC 1600 JOHN F …